Inhalation Sciences Sweden AB (XSAT:ISAB) Other Financing: kr-2.93 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:ISAB Inhalation Sciences Sweden AB XSAT:ISAB
29 GF Score
Price kr0.22
GF Value kr0.39
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Inhalation Sciences Sweden AB Other Financing?

Inhalation Sciences Sweden AB XSAT:ISAB -1.79% 29 Other Financing is kr-2.93 Mil as of Mar. 2026. GuruFocus rates XSAT:ISAB with a GF Score™ of 29/100 and a GF Value™ of kr0.39 (Possible Value Trap). The stock has 5 warning signs investors should review.

Inhalation Sciences Sweden AB's Other Financing for the three months ended in Mar. 2026 was kr-0.67 Mil.

Inhalation Sciences Sweden AB's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was kr-2.93 Mil.

Inhalation Sciences Sweden AB Other Financing Historical Data

* Premium members only.

The historical data trend for Inhalation Sciences Sweden AB's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inhalation Sciences Sweden AB Other Financing Chart

Inhalation Sciences Sweden AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.59 0.00 -22.96 0.00 -2.39

Inhalation Sciences Sweden AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -2.23 -0.03 0.00 -0.67
XSAT:ISAB
29GF Score
Inhalation Sciences Sweden AB XSAT:ISAB
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inhalation Sciences Sweden AB Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-2.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of kr-2.93 Mil mean?
Inhalation Sciences Sweden AB (XSAT:ISAB) has a Other Financing of kr-2.93 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Inhalation Sciences Sweden AB and its competitors.
Is Inhalation Sciences Sweden AB's Other Financing too high?
Inhalation Sciences Sweden AB's current Other Financing is kr-2.93 Mil. Overall, Inhalation Sciences Sweden AB has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Inhalation Sciences Sweden AB's Other Financing compare to ABT and SYK?
Inhalation Sciences Sweden AB's Other Financing of kr-2.93 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Medical Devices & Instruments company?
A good Other Financing depends on the Medical Devices & Instruments industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Inhalation Sciences Sweden AB and its competitors. Inhalation Sciences Sweden AB's current Other Financing is kr-2.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inhalation Sciences Sweden AB stock overvalued right now?
Based on GuruFocus' analysis, Inhalation Sciences Sweden AB (XSAT:ISAB) is currently considered Possible Value Trap. The stock's GF Value™ is kr0.39, compared to a current price of kr0.22 — trading 43.8% below its estimated fair value. The current Other Financing is kr-2.93 Mil. Inhalation Sciences Sweden AB's overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Inhalation Sciences Sweden AB (XSAT:ISAB), the current Other Financing is kr-2.93 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Inhalation Sciences Sweden AB (XSAT:ISAB) Overvalued in 2026?

Based on GuruFocus' analysis, Inhalation Sciences Sweden AB stock appears to be undervalued. The current stock price of kr0.22 is trading 43.8% below its estimated GF Value™ of kr0.39. GuruFocus considers Inhalation Sciences Sweden AB to be Possible Value Trap.

Key valuation signals for XSAT:ISAB:

  • Other Financing: kr-2.93 Mil
  • GF Value™: kr0.39 vs. price of kr0.22 (43.8% below fair value)
  • GF Score™: 29/100 with 5 warning signs

No single metric tells the full story. See the XSAT:ISAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Inhalation Sciences Sweden AB Business Description

Address Halsovagen 7, Huddinge, SWE, 141 57
Inhalation Sciences Sweden AB develops and commercializes patented lab instrument for inhalation research. Its products include PreciseInhale an advanced laboratory system used to measure inhaled particles and their effect on lungs, and LaminarPace tool for drying small amounts of the drug substance.
29GF Score

Get the complete analysis for XSAT:ISAB

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.22
Price
kr0.39
GF Value